Related references
Note: Only part of the references are listed.Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Treatment-related Myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
Myron S. Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy
Ruben Niesvizky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients
Gareth J. Morgan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma
Annuska M. Glas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gliosarcoma with intramedullary spinal metastases: A case report and review of the literature
Sean Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
R. Baz et al.
ANNALS OF ONCOLOGY (2006)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism
Kena C. Miller et al.
LEUKEMIA & LYMPHOMA (2006)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
AK Gandhi et al.
LEUKEMIA RESEARCH (2006)
T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil
H Mellstedt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Immunomodulating drugs for chronic lymphocytic leukaemia
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
A Chanan-Khan et al.
BLOOD (2005)
Lenalidomide and thalidomide: Mechanisms of action - Similarities and differences
KC Anderson
SEMINARS IN HEMATOLOGY (2005)
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
FJ Hernandez-Ilizaliturri et al.
CLINICAL CANCER RESEARCH (2005)
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
G Görgün et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
JC Byrd et al.
BLOOD (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL) comparison of indolent and progressive disease
S Kiaii et al.
MEDICAL ONCOLOGY (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
H Kaufmann et al.
BLOOD (2004)
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
PH Schafer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Cytokine modulation of nuclear factor-κB activity in B-chronic lymphocytic leukemia
A Zaninoni et al.
EXPERIMENTAL HEMATOLOGY (2003)
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
S Lentzsch et al.
LEUKEMIA (2003)
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
D Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
JC Byrd et al.
BLOOD (2003)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia
M Coleman et al.
LEUKEMIA & LYMPHOMA (2002)
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
NE Kay et al.
LEUKEMIA (2002)
Treatment of Waldenstrom's macroglobulinemia with thalidomide
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Immunotherapeutic and antitumour potential of thalidomide analogues
JB Marriott et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2001)
Share Paper
